Research Article

Association between Cervical Lymph Node Metastasis and the Incidence of Radiation-Induced Hypothyroidism in Nasopharyngeal Carcinoma

Ling Zhou,1 Jia Chen,2 Chang-Juan Tao,3 Qing-Feng Zhao,4 Yu-Ming Chen,1 Xiao-Zhong Chen,3 Ming Chen,3,5 Zhong-Hua Yu,6 and Yuan-Yuan Chen3

1Department of Radiation Oncology, Dongguan People’s Hospital, Dongguan, China
2Research Center for Healthcare Data Science, Zhejiang Lab, Hangzhou, China
3Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
4Information Department, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
5Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China
6Department of Oncology, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, China

Correspondence should be addressed to Yuan-Yuan Chen; chenyy2@sysucc.org.cn

Received 12 October 2021; Accepted 27 December 2021; Published 31 January 2022

Copyright © 2022 Ling Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. It is controversial and unclear how N-stage would increase the risk of incidence of hypothyroidism (HT) for patients with nasopharyngeal carcinoma (NPC) after radiotherapy. Our study aimed to explore the correlation between cervical lymph node metastasis and the incidence of HT in NPC. Materials and Methods. A total of 206 patients with NPC treated at the Cancer Hospital of University of Chinese Academy of Sciences, and their clinical information were retrospectively collected. A series of univariate logistic regression models were performed to explore the association of clinical and lymph node indices with the development of HT. Significant features in univariate analysis were then used to construct three prediction models, for HT prediction using multivariate logistic regression based on Bayesian information criterion. Prediction performance of those models was measured by area under the receiver operating characteristic curve (AUC) using 10-fold cross-validation. Results. A total of 111 patients developed HT, and the incidence of HT in N2–3 and N0–1 patients was 58.82% and 44.29%, respectively. Compared to Model 1 (consisted of pretreatment TSH concentration, thyroid volume, and N-stage) whose AUCs were 0.801 and 0.766 in training and validation sets, with N-stage be replaced by shortest distance from thyroid, Model 2 achieved more stable AUCs of 0.824 and 0.801. While with numbers of positively lymph nodes in Level IIb additionally added, Model 3 improved its AUCs to 0.841 and 0.813. Conclusion. The shortest distance between the lymph nodes and thyroid gland and the number of lymph nodes in IIb are better predictors of radiation-induced HT than the N-stage.

1. Introduction

Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumors in the head and neck region, and it is particularly prevalent in East and Southeast Asian countries [1] Radiotherapy is the main treatment, and cervical lymph nodes are routinely included in the irradiation field because >75% newly treated patients with NPC have cervical lymph node metastasis [2]. The thyroid gland is located in the front of the neck, which makes it an easy target for high-dose radiation exposure, resulting in radiation-induced hypothyroidism (HT) and poor quality of life [3, 4]. The most common symptoms of HT are fatigue, lethargy, cold intolerance, weight gain, constipation, change in voice, and dry skin, although clinical presentation can differ with age and sex. Some patients in the early stage show no
obvious symptoms, and hence, treatment is often delayed due to missed diagnosis. However, the cardiovascular, nervous, digestive, and circulatory systems can be involved in the late stage of the disease [5]. Therefore, early and timely prediction of HT is important in the prognosis of patients with NPC. At present, the clinical factors including tumor node metastasis (TNM)-stage, pretreatment thyroid-stimulating hormone (TSH) concentration, thyroid volume, sex, and chemotherapy are considered related to HT.

Among the abovementioned factors, TNM-stage is an important basis for treatment and judging prognosis in patients with NPC [6]. Specifically, the N-stage represents lymph nodes stage, which refers to the size and extent of cervical lymph node metastasis. In our previous study, an independent predictor of the incidence of HT [7], which is consistent with other studies [8, 9]. Nonetheless, the relationship between N-stage and incidence of HT is still controversial, and as yet, there is no independent study to explore its internal relationship. Some researchers believe that advanced N-stage can increase the incidence of HT by influencing the irradiation dose of the neck [8, 9]. However, it is still unknown how the N-stage affects the cervical radiation dose, specifically whether the size and number of metastatic lymph nodes or the distance between metastatic lymph nodes and thyroid gland are related to the incidence of HT. Therefore, the purpose of this study was to further explore the internal relationship between the incidence of HT and cervical lymph node metastasis to build the best prediction model for radiation-induced HT and guide individual treatment accordingly.

2. Materials and Methods

2.1. Patients. In all, 1000 patients with NPC treated at the Cancer Hospital of University of Chinese Academy of Sciences from January 2015 to August 2018 were retrospectively analyzed. Of these, 206 patients whom the inclusion criteria were enrolled. The eligibility criteria included patients with pathologically confirmed primary NPC receiving radical intensity-modulated radiotherapy (IMRT) at our hospital; those with complete clinical data and thyroid function test results before and after radiotherapy; and those with >1 year follow-up with thyroid function tests. The exclusion criteria were patients who had already received radiotherapy before treatment at our hospital or who had a dysfunction with the hypothalamic-pituitary-thyroid (HPT) axis.

2.2. Treatment. All patients received radical IMRT. Patients in the supine position were fixed with the head-neck-shoulder thermoplastic mask. The computed tomography simulation (CT-sim) scanned from the skull base to the sternal angle with a thickness of 3 mm. Magnetic resonance imaging (MRI) scan was obtained in the same posture with an immobilization mode (Siemens Verio 3.0T). The CT-sim and MRI scan images were transmitted into RayStation 4.0, and the delineated tumor area on the CT image was combined with the MR image. The gross tumor volume (GTV) included the primary disease (GTVnx) and the metastatic lymph nodes (GTVnd). High-risk clinical target volume (CTV-1) included soft tissue adjacent to GTV. Low-risk CTV (CTV-2) included bilateral lymphatic drainage regions. PGTVnx, PGTVnd, PTV-1, and PTV-2 were established by adding 3 to 5 mm to the GTVnx, GTVnd, CTV-1, and CTV-2, respectively. The prescription dose of PGTVnx, PGTVnd, PTV-1, and PTV-2 were 70.40 Gy, 68.80 Gy, 64.00 Gy, and 54.40 Gy, respectively, and it was completed in 32 fractions. Dose prescription of normal tissue was stated as follows: The maximum dose of the brainstem, optic nerves, and chiasma were 54 Gy, while that of the pituitary was 50 Gy; no dose constraint was given for the thyroid gland during optimization of all IMRT plans. Around 194 patients (94.17%) received platinum-based neoadjuvant chemotherapy, concurrent chemotherapy, or adjuvant chemotherapy, while 12 patients (5.83%) did not receive any chemotherapy.

2.3. Redrawing of Metastatic Lymph Nodes. Diagnostic criteria of metastatic lymph nodes: (1) Minimum diameter of lymph nodes with a minimal axial diameter of ≥11 mm in the submandibular and digastic region, the shortest axial diameter of >5 mm in the retropharyngeal lymph nodes, and more than 10 mm in other lymph node regions. (2) Three or more lymph nodes in the same region with a minimal axial diameter of 8 mm in lymph node drainage regions of the tumor. (3) Central necrosis or circular enhancement of lymph nodes. (4) All nodes that show irregular enhancement and mutual fusion should be considered metastatic [10].

According to the diagnostic criteria of lymph node metastasis, a senior doctor redrew the metastatic lymph nodes of 206 patients, divided all lymph nodes according to the new guidelines for delineation of the cervical lymph nodes, and recorded their number and maximum lymph node size (the minimum axial diameter) [11].

2.4. Measure the Shortest Distance between Metastatic Lymph Nodes and Thyroid Gland. The thyroid gland was expanded 1, 2, 3, 4, and 5 cm, respectively, and the shortest distance between the metastatic lymph nodes and thyroid gland was recorded, such as 0 to 1 cm, 1 to 2 cm, 2 to 3 cm, 3 to 4 cm, 4 to 5 cm, and >5 cm. If there was no cervical lymph node metastasis, the default measurement was considered as >5 cm.

2.5. Thyroid Function Test. HT was defined as TSH concentrations above the reference range (0.380–4.340 IU/mL) and FT4 concentrations within or below the normal range (0.81–1.89 ng/dL) [5]. Thyroid function test was using the electrochemiluminescence method with the SIEMENS ADVIA Centaur XP, followed up at least every 6 months after radiotherapy.

2.6. Statistical Analysis. First of all, means and standard deviations were used to describe variables with normal distribution, median (Q25–Q75) were used to describe variables with non-normal distribution, and frequency and
percentages were used to describe categorical variables. Their differences were then correspondingly compared using a t-test, Wilcoxon rank-sum test (or Mann–Whitney U test), and chi-square test (or Fisher’s exact probability), respectively. Second, a series of univariate logistic regression models were analyzed to examine which of the clinical and lymph node indices were related to the development of HT. Third, for best prediction of HT and further exploration of its association with cervical lymph nodes, multivariate logistic regression was first constructed based on factors from (1) significant clinical features in the univariate analysis, and then, the N-stage in (1) was replaced by significantly positive lymph-node-related factors, respectively (i.e., the shortest distance between the metastatic lymph nodes and thyroid gland together with the size of positive lymph nodes in each neck area, and distance from numbers of metastatic cervical lymph nodes) to build Models 2 and 3. The best fit for those models was determined by statistical fit (Bayesian information criterion [BIC]). In addition, a heat map was drawn to show the collinearity of the number and size of metastatic cervical lymph nodes in each level. To avoid over-fitting, numbers and size of metastatic cervical lymph nodes were separately included in the aforementioned models (i.e., Models 2 and 3) instead of aggregation. Furthermore, model performance was assessed and compared by areas under receiver operating characteristic curve (AUCs) using 10-fold cross-validation. Finally, a nomogram was built for individualized prediction according to the model with best performance. \( P < 0.05 \) was considered statistically significant. All analyses were performed using R, version 3.6.2.

3. Results

(1) Clinical characteristics: The average age of the 206 patients was 51.37 ± 10.71 years. A total of 111 (53.88%) of the 206 patients developed HT due to radiation therapy, and the incidence of HT in \( N_{2-3} \) patients and \( N_{0-1} \) patients was 58.82% (80/136) and 44.29% (31/70), respectively, after a median follow-up time of 21 months. Table 1 shows the general clinical characteristics of 206 patients with NPC.

(2) Cervical lymph nodes metastasis: The rate of cervical lymph node metastasis in the group was 96.12% (198/206), and the detailed distribution is as follows: Level IIa was the highest incidence (91.75%) of lymph node metastasis, followed by Level IIb (90.29%). It was found that the number and size of cervical lymph nodes in each level had strong collinearity by heat map, as shown in Figure 1.

(3) Univariate analysis for HT. Univariate analysis showed that sex, N-stage, pretreatment TSH concentration, thyroid volume, and the shortest distance between metastatic lymph nodes and thyroid gland were correlated with HT. In addition, the number of metastatic lymph nodes in Levels IIa, IIb, III, IVa, and Va and the maximum diameter of lymph nodes in Levels IIb and IVa were also associated with HT. Among them, advanced N-stage (\( N_{2-3} \)), high pretreatment TSH concentration, small thyroid volume, large distance between the metastatic lymph nodes and thyroid gland, and large number of metastatic lymph nodes in Level IIb were the risk factors of HT. There was no significant difference in other factors such as age, clinical stage, and chemotherapy (Table 2).

(4) Multivariate analysis and prediction model: Based on BIC, pretreatment TSH concentration, thyroid volume, and N-stage were built on the best clinical-based model (Model 1 in Table 3) to predict the incidence of radiation-induced HT. Compared to Model 1 whose AUCs were 0.801 and 0.766 in training and validation sets, with N-stage be replaced by shortest distance from thyroid, Model 2 achieved more stable AUCs of 0.824 and 0.801. While with numbers of positive lymph nodes in Level IIb additionally added, Model 3 improved its AUCs to 0.841 and 0.813 (Figure 2).

(5) Nomogram prediction model: With comprehensive consideration of the prediction performance and simplicity of models, a nomogram based on three-variables was constructed, including the pretreatment TSH concentration, thyroid volume, and the shortest distance between the metastatic lymph nodes and thyroid gland. Model 2 was regarded as the best model of radiation-induced HT prediction, and individualized prediction is shown in Figure 3.

4. Discussion

HT is one of the common side effects of NPC after radiotherapy, with an incidence of 20% to 60%, which mainly occurred 1 to 2 years after radiotherapy [12, 13]. Thyroid hormone replacement with levothyroxine is the standard treatment for patients with HT. However, a substantial proportion of patients treated with levothyroxine have persistent complaints [5], which has prompted the question of whether the incidence of HT can be predicted early, in order to screen high-risk patients and improve their quality of life as much as possible. At present, there are few studies on the risk factors related to radiation-induced HT, and its incidence is mainly related to radiation dose, chemotherapy, clinical stage, and other factors [4, 14]. Our previous study found that N-stage, radiation dose, and volume of thyroid are independent predictors of HT, combined with N-stage, dosimetric parameters, and volume to build an NTCP model [7], but the performance was not very good, which was also the limitation of most similar studies. To our best knowledge, this is the first retrospective study to analyze the number, size, and the shortest distance between the metastatic lymph nodes and thyroid and the correlation between these and the incidence of HT. Furthermore, we also constructed a prediction model of HT based on the related factors of metastatic lymph nodes. The results showed that the shortest distance between the metastatic lymph nodes and thyroid achieved the best prediction of HT and improved the prediction performance. In addition, the NTCP
Table 1: The general clinical characteristics of 206 patients with nasopharyngeal carcinoma.

| Variables                        | Euthyroidism | Hypothyroidism | $P$   |
|----------------------------------|--------------|----------------|-------|
| Sex (%)                          |              |                |       |
| Male                             | 73 (76.8)    | 63 (56.8)      | 0.004*|
| Female                           | 22 (23.2)    | 48 (43.2)      |       |
| Age (mean [SD])                  | 52.81 (10.61)| 50.14 (10.68)  | 0.075 |
| Pretreatment TSH concentration   | 1.29 (0.92, 1.74) | 2.29 (1.58, 3.06) | <0.001***|
| Volume (cm$^3$)                  | 16.16 (13.43, 19.98) | 12.82 (10.79, 16.13) | <0.001***|
| $T$-stage (%)                    |              |                | 1     |
| $T_1$–2                          | 18 (18.9)    | 21 (18.9)      |       |
| $T_3$–4                          | 77 (81.1)    | 90 (81.1)      |       |
| $N$-stage (%)                    |              |                | 0.067 |
| $N_0$–1                          | 39 (41.1)    | 31 (27.9)      |       |
| $N_2$–3                          | 56 (58.9)    | 80 (72.1)      |       |
| $M$-stage (%)                    |              |                | 0.656 |
| $M_0$                            | 92 (96.8)    | 105 (94.6)     |       |
| $M_1$                            | 3 (3.2)      | 6 (5.4)        |       |
| Clinical stage (%)               |              |                | 0.981 |
| I–II                             | 7 (7.4)      | 7 (6.3)        |       |
| III–IV                           | 88 (92.6)    | 104 (93.7)     |       |
| Neoadjuvant chemotherapy (%)     |              |                |       |
| No                               | 7 (7.4)      | 5 (4.5)        | 0.564 |
| Yes                              | 88 (92.6)    | 106 (95.5)     |       |
| Distance from thyroid (%)        |              |                | 0.905**|
| 0–1 cm                           | 13 (13.7)    | 29 (26.1)      |       |
| 1–2 cm                           | 16 (16.8)    | 30 (27.0)      |       |
| 2–3 cm                           | 31 (32.6)    | 31 (27.9)      |       |
| >3 cm                            | 35 (36.8)    | 21 (18.9)      |       |
| Number. Level Ib (%)             |              |                | 0.538 |
| 0                                | 87 (91.6)    | 100 (90.1)     |       |
| 1–2                              | 7 (7.4)      | 11 (9.9)       |       |
| ≥3                               | 1 (1.1)      | 0 (0.0)        |       |
| Number. Level IIA (%)            |              |                | 0.046*|
| 0                                | 12 (12.6)    | 5 (4.5)        |       |
| 1–2                              | 69 (72.6)    | 95 (85.6)      |       |
| ≥3                               | 14 (14.7)    | 11 (9.9)       |       |
| Number. Level IIB (%)            |              |                | 0.001**|
| 0                                | 16 (16.8)    | 4 (3.6)        |       |
| 1–2                              | 48 (50.5)    | 78 (70.3)      |       |
| ≥3                               | 31 (32.6)    | 29 (26.1)      |       |
| Number. Level III (%)            |              |                | 0.048*|
| 0                                | 36 (37.9)    | 27 (24.3)      |       |
| 1–2                              | 42 (44.2)    | 51 (45.9)      |       |
| ≥3                               | 17 (17.9)    | 33 (29.7)      |       |
| Number. Level IVa (%)            |              |                | 0.006**|
| 0                                | 70 (73.7)    | 58 (52.3)      |       |
| 1–2                              | 21 (22.1)    | 41 (36.9)      |       |
| ≥3                               | 4 (4.2)      | 12 (10.8)      |       |
| Number. Level IVb (%)            |              |                | 0.173 |
| 0                                | 95 (100.0)   | 107 (96.4)     |       |
| 1–2                              | 0 (0.0)      | 4 (3.6)        |       |
| Number. Level Va (%)             |              |                | 0.04* |
| 0                                | 64 (67.4)    | 58 (52.3)      |       |
| 1–2                              | 30 (31.6)    | 47 (42.3)      |       |
| ≥3                               | 1 (1.1)      | 6 (5.4)        |       |
| Number. Level Vb (%)             |              |                | 0.163 |
| 0                                | 81 (85.3)    | 85 (76.6)      |       |
| 1–2                              | 14 (14.7)    | 26 (23.4)      |       |
| Number. Level Vc (%)             |              |                | 1     |
| 0                                | 93 (97.9)    | 108 (97.3)     |       |
| 1–2                              | 2 (2.1)      | 3 (2.7)        |       |
| Number. Level VIIa (%)           |              |                | 0.898 |
model with the number of lymph nodes in Level IIb also showed good performance.

The correlation between N-stage and HT is still controversial. Fujiwara et al. [9] reported that only the radiation field that included the whole neck had a significant correlation with the development of HT, as irradiation of cervical lymph nodes can increase the incidence of HT in patients with head and neck cancer. Huang et al. [15] retrospectively analyzed 345 patients with NPC treated with IMRT and found that N1–3 patients were more likely to develop HT than N0 patients, but the internal relationship between lymph node metastasis and the incidence of HT was not explored. In contrast with the aforementioned conclusion, Koc and Capoglu [16] suggested that the clinical stage of NPC has no effect on the incidence of HT. In our previous study, N-stage played a major role in the NTCP model for predicting HT in NPC patients, and the incidence of HT in N2–3 patients and N0–1 patients was 58.82% and 44.29%, respectively [7]. The results of this study showed that N-stage can predict the incidence of HT again, and patients with advanced N-stage will inevitably receive higher irradiated volume of the tumor, resulting in a higher risk of thyroid irradiation. Model 1 can predict the incidence of HT by including N-stage, thyroid volume, and pretreatment TSH concentration. Compared with Model 1, Model 2 involved the shortest distance between the metastatic lymph nodes and thyroid gland instead of N-stage and achieved a better and more stable prediction, with its AUC increasing from 0.801 to 0.824 and 0.766 to

| Variables | Euthyroidism | Hypothyroidism | P |
|-----------|-------------|----------------|---|
| 0         | 24 (25.3)   | 30 (27.0)      |    |
| 1–2       | 71 (74.7)   | 81 (73.0)      | 0.48 |
| Maxdiameter. Level Ib (%) |          |                |    |
| 0 cm      | 87 (91.6)   | 100 (90.1)     |    |
| 0–1 cm    | 7 (7.4)     | 7 (6.3)        |    |
| ≥1 cm     | 1 (1.1)     | 4 (3.6)        |    |
| Maxdiameter. Level IIa (%) |          |                | 0.073 |
| 0 cm      | 12 (12.6)   | 5 (4.5)        |    |
| 0–1 cm    | 56 (58.9)   | 65 (58.6)      |    |
| ≥1 cm     | 27 (28.4)   | 41 (36.9)      |    |
| Maxdiameter. Level IIb (%) |          |                | 0.006** |
| 0 cm      | 16 (16.8)   | 4 (3.6)        |    |
| 0–1 cm    | 41 (43.2)   | 57 (51.4)      |    |
| ≥1 cm     | 38 (40.0)   | 50 (45.0)      |    |
| Maxdiameter. Level III (%) |          |                | 0.07 |
| 0 cm      | 36 (37.9)   | 27 (24.3)      |    |
| 0–1 cm    | 47 (49.5)   | 72 (64.9)      |    |
| ≥1 cm     | 12 (12.6)   | 12 (10.8)      |    |
| Maxdiameter. Level IVa (%) |          |                | 0.007** |
| 0 cm      | 70 (73.7)   | 58 (52.3)      |    |
| 0–1 cm    | 22 (23.2)   | 46 (41.4)      |    |
| ≥1 cm     | 3 (3.2)     | 7 (6.3)        |    |
| Maxdiameter. Level IVb (%) |          |                | 0.251 |
| 0 cm      | 95 (100.0)  | 107 (96.4)     |    |
| 0–1 cm    | 0 (0.0)     | 2 (1.8)        |    |
| ≥1 cm     | 0 (0.0)     | 2 (1.8)        |    |
| Maxdiameter. Level Va (%) |          |                | 0.079 |
| 0 cm      | 64 (67.4)   | 58 (52.3)      |    |
| 0–1 cm    | 25 (26.3)   | 45 (40.5)      |    |
| ≥1 cm     | 6 (6.3)     | 8 (7.2)        |    |
| Maxdiameter. Level Vb (%) |          |                | 0.238 |
| 0 cm      | 81 (85.3)   | 85 (76.6)      |    |
| 0–1 cm    | 12 (12.6)   | 20 (18.0)      |    |
| ≥1 cm     | 2 (2.1)     | 6 (5.4)        |    |
| Maxdiameter. Level Vc (%) |          |                | 1 |
| 0 cm      | 93 (97.9)   | 108 (97.3)     |    |
| 0–1 cm    | 2 (2.1)     | 2 (1.8)        |    |
| ≥1 cm     | 0 (0.0)     | 1 (0.9)        |    |
| Maxdiameter. Level VIIa (%) |          |                | 0.653 |
| 0 cm      | 24 (25.3)   | 30 (27.0)      |    |
| 0–1 cm    | 48 (50.5)   | 60 (54.1)      |    |
| ≥1 cm     | 23 (24.2)   | 21 (18.9)      |    |
| Number. all | 7.00 (5.00, 10.00) | 9.00 (6.00, 11.00) | 0.008** |
| Maxdiameter. all | 1.04 (0.81, 1.38) | 1.15 (0.94, 1.54) | 0.039* |

The values in the table are N (%) or median (Q25–Q75) unless otherwise indicated; Maxdiameter: maximum diameter; *P < 0.05, **P < 0.01, ***P < 0.001.
0.801 in the training and test sets, respectively. This probably indicated that the shortest distance between the metastatic lymph nodes and thyroid gland has a greater effect on HT than N-stage, even though both related factors may affect the incidence of HT through radiation dose. N-stage cannot reflect the minimum distance between lymph nodes and thyroid gland. In addition, compared with Model 2, Model 3 included not only all the factors in Model 2 but also the number of metastatic lymph nodes in Level IIb, which also increased the AUC values of the training and test sets from 0.824 to 0.841 and 0.801 to 0.813, respectively. This suggested that the number of lymph nodes in Level IIb could predict the incidence of HT, which may be related to most of the patients with advanced N-stage who had a higher rate of lymph node metastasis in Level IIb. Therefore, when establishing the NTCP model of radiation-induced HT in NPC, it may be necessary to consider the effect of the shortest distance between lymph nodes and thyroid gland and the number of lymph nodes in Level IIb. In a word, considering the prediction effect and simplicity of the model, Model 2 is the best for building an NTCP model for HT in NPC patients.

Consistent with the results of previous studies [13, 17], we found that thyroid volume and pretreatment TSH concentration are independent predictors of HT, as patients with smaller thyroid volume are more likely to develop HT. Moreover, thyroid volume is an independent predictor of HT because a smaller thyroid volume and less thyroid hormone storage naturally lead to higher TSH value [17]. In addition, high TSH concentration before radiotherapy was also a risk factor for HT; the higher the pretreatment TSH concentration, the higher the incidence of HT. In clinical practice, patients with small thyroid volume; high TSH concentration before radiotherapy; and metastatic lymph nodes close to the thyroid gland should be closely followed-up for thyroid function. The nomogram based on Model 2 visualizes the individual prediction, closely followed-up for thyroid function. The nomogram has clinical guiding significance.

Our study has some limitations. First, the median follow-up (21 months) was relatively short, which may have negatively influenced the evaluation of long-term side effects of radiation-induced HT. Second, there is an inevitable bias because of the retrospective nature of the study. Third, the number of patients in this study was relatively small.
| Variables                        | Beta   | OR (95% CI)          | P       |
|---------------------------------|--------|----------------------|---------|
| Age                             | -0.02  | 0.98 (0.95–1.00)     | 0.076   |
| Sex                             | 0.95   | 2.53 (1.38–4.64)     | 0.003***|
| Pretreatment TSH concentration  | 1.2    | 3.33 (2.24–4.95)     | <0.001***|
| Volume (cm\(^3\))              | -0.13  | 0.88 (0.83–0.94)     | <0.001***|
| T-Stage (T1–2 vs. T3–4)         | 0.00   | 1.00 (0.50–2.01)     | 0.996   |
| N-stage (N2–3 vs. N0–1)         | 0.59   | 1.80 (1.00–3.22)     | 0.048*  |
| M-Stage (M1 vs. M0)             | 0.58   | 1.75 (0.43–7.21)     | 0.437   |
| Clinical stage (III–IV vs I–II) | 0.17   | 1.18 (0.40–3.50)     | 0.763   |
| Neoadjuvant chemotherapy (yes vs. no) | 0.52   | 1.69 (0.52–5.50)     | 0.386   |
| Distance from thyroid 1–2 cm (vs. 0–1 cm) | -0.17 | -0.17 (0.34–2.05) | 0.703   |
| Distance from thyroid 2–3 cm (vs. 0–1 cm) | -0.8  | -0.80 (0.20–1.02) | 0.056   |
| Distance from thyroid >3 cm (vs. 0–1 cm) | -1.31 | -1.31 (0.12–0.63) | 0.002** |
| N.Ib (1–2 vs 0)                 | 0.31   | 0.31 (0.51–3.68)     | 0.536   |
| N.Ia (1–2 vs 0)                 | -14.71 | -14.71 (0.00–Inf)    | 0.987   |
| N.Ia (3+ vs 0)                  | 1.2    | 1.20 (1.11–9.81)     | 0.031*  |
| N.Ib (1–2 vs 0)                 | 1.87   | 1.87 (2.05–20.59)    | 0.001** |
| N.Ib (3+ vs 0)                  | 1.32   | 1.32 (1.12–12.51)    | 0.032*  |
| N.III (1–2 vs 0)                | 0.48   | 0.48 (0.85–3.09)     | 0.143   |
| N.III (3+ vs 0)                 | 0.95   | 0.95 (2.20–5.58)     | 0.015*  |
| N.IVa (1–2 vs 0)                | 0.86   | 0.86 (1.25–4.43)     | 0.008** |
| N.IVa (3+ vs 0)                 | 1.29   | 1.29 (1.11–11.83)    | 0.033*  |
| N.Ib (1–2 vs 0)                 | 0.55   | 0.55 (1.10–3.80)     | 0.024   |
| N.Ia (1–2 vs 0)                 | 1.89   | 1.89 (0.77–56.65)    | 0.084   |
| N.Ib (1–2 vs 0)                 | 0.57   | 0.57 (0.86–3.63)     | 0.119   |
| N.Vc (1–2 vs 0)                 | 1.29   | 1.29 (0.21–7.90)     | 0.782   |
| N.Va (1–2 vs 0)                 | 0.91   | 0.91 (0.49–1.70)     | 0.774   |
| Maxdiameter.Ib (0, 1 cm)        | -0.14  | -0.14 (0.29–2.58)    | 0.762   |
| Maxdiameter.Ib ≥ 1 cm           | 1.25   | 1.25 (0.38–31.69)    | 0.269   |
| Maxdiameter.Ila (0, 1 cm)       | 1.02   | 1.02 (0.92–8.39)     | 0.669   |
| Maxdiameter.Ila ≥ 1 cm          | 1.29   | 1.29 (1.05–11.32)    | 0.028*  |
| Maxdiameter.Ifb (0, 1 cm)       | 1.72   | 1.72 (1.23–17.86)    | 0.004***|
| Maxdiameter.Ifb ≥ 1 cm          | 1.66   | 1.66 (1.63–17.03)    | 0.006** |
| Maxdiameter.III (0, 1 cm)       | 0.71   | 0.71 (1.00–2.00)     | 0.224*  |
| Maxdiameter.III ≥ 1 cm          | 0.29   | 0.29 (0.52–3.42)     | 0.525   |
| Maxdiameter.IVa (0, 1 cm)       | 0.91   | 0.91 (1.36–4.67)     | 0.003** |
| Maxdiameter.IVa ≥ 1 cm          | 1.04   | 1.04 (0.70–13.38)    | 0.146   |
| Maxdiameter.IVb (0, 1 cm)       | 15.45  | 15.45 (0.00–Inf)     | 0.988   |
| Maxdiameter.IVb ≥ 1 cm          | 15.45  | 15.45 (0.00–Inf)     | 0.988   |
| Maxdiameter.IVa (0, 1 cm)       | 0.69   | 0.69 (0.19–3.64)     | 0.026*  |
| Maxdiameter.IVa ≥ 1 cm          | 0.39   | 0.39 (0.48–4.49)     | 0.498   |
| Maxdiameter.Vb (0, 1 cm)        | 0.46   | 0.46 (0.73–3.46)     | 0.244   |
| Maxdiameter.Vb ≥ 1 cm           | 1.05   | 1.05 (0.56–14.58)    | 0.206   |
| Maxdiameter.Vc (0, 1 cm)        | -0.15  | -0.15 (0.12–6.23)    | 0.882   |
| Maxdiameter.Vc ≥ 1 cm           | 14.42  | 14.42 (0.00–Inf)     | 0.987   |
| Maxdiameter.VIIa (0, 1 cm)      | 0.00   | -0.00 (0.52–1.93)    | 1       |
| Maxdiameter.VIIa ≥ 1 cm         | -0.31  | -0.31 (0.33–1.62)    | 0.441   |
| N: all                          | 0.31   | 1.11 (1.03–13.19)    | 0.004***|
| Maxdiameter.all                  | 0.59   | 1.11 (1.03–3.18)     | 0.04*   |

OR = odds ratio; CI = confidence interval; Distance from thyroid = the shortest distance between metastatic lymph nodes and the thyroid gland; N = number. *P < 0.05, **P < 0.01, ***P < 0.001.
Table 3: Multivariate analysis of radiation-induced HT.

| Variables (ref)                      | Model 1 |          | P    | Model 2 |          | P    | Model 3 |          | P    |
|--------------------------------------|---------|----------|------|---------|----------|------|---------|----------|------|
|                                      | Beta    | OR (95% CI) |     | Beta    | OR (95% CI) |     | Beta    | OR (95% CI) |     |
| Constant                             | −1.08   | 0.34 (0.08–1.46) | 0.146 | 2.30    | 0.48–11.12) | 0.300 | −0.67   | 0.05–4.89) | 0.563 |
| N stage                              | 0.79    | 2.20 (1.12–4.33) | 0.023 |         |          |      |         |          |      |
| Pretreatment TSH                      | 1.14    | 3.12 (2.07–4.72) | <0.001 | 1.23    | 3.41 (2.20–5.29) | <0.001 | 1.26    | 3.54 (2.25–5.57) | <0.001 |
| Thyroid volume                        | −0.09   | 0.91 (0.85–0.98) | 0.010 | −0.08   | 0.92 (0.86–0.99) | 0.018 | −0.09   | 0.85–0.99) | 0.020 |
| Shortest distance from thyroid        |         |          |      | −0.62   | 0.54 (0.39–0.74) | <0.001 | −0.56   | 0.41–0.80) | 0.001 |
| Numbers of positive lymph nodes in IIb area | 1–2 (ref: 0) |      |      | 1.69    | 5.42 (1.40–20.97) | 0.014 | 0.79    | 2.19 (0.52–9.19) | 0.282 |
| 3+ (ref: 0)                           |         |          |      |         |          |      |         |          |      |

Figure 2: Predictive power comparison between three nomogram models under multivariate analysis: (a) box plot of AUC distribution of the 10 logistic regression models in each 10-fold cross-validation. (b) Training ROC curves for Model 1 (yellow), Model 2 (blue), and Model 3 (purple). The AUCs of the three curves are 0.801, 0.824, and 0.841, respectively. (c) Testing ROC curves for Model 1 (yellow), Model 2 (blue), and Model 3 (purple). The AUCs of the three curves are 0.766, 0.801, and 0.813, respectively.
Thus, it is necessary to design a prospective, long-term follow-up study in a larger patient cohort to build a better prediction model of radiation-induced HT.

5. Conclusion

The shortest distance between metastatic lymph nodes and the thyroid gland and/or the number of lymph nodes in Level IIb could better predict radiation-induced HT than the N-stage.

Data Availability

The data sets supporting the conclusions of this article are included within the article.

Ethical Approval

The study was approved by Medical Ethics Committee of Zhejiang Cancer Hospital. The committee’s reference number: IRB-2019-87.

Conflicts of Interest

The authors declare that there are no competing interests.

Authors’ Contributions

Ling Zhou and Jia Chen contributed equally to this work.

Acknowledgments

The authors acknowledge the contributions of all members in our research team to the article. This work was supported by the Dongguan People’s Hospital.

References

[1] Y.-P. Chen, A. T. C. Chan, Q.-T. Le, P. Blanchard, Y. Sun, and J. Ma, "Nasopharyngeal carcinoma," The Lancet, vol. 394, no. 10192, pp. 64–80, 2019.
[2] Z. Lin, V. W.-C. Wu, J. Lin, H. Feng, and L. Chen, "A longitudinal study on the radiation-induced thyroid gland changes after external beam radiotherapy of nasopharyngeal carcinoma," Thyroid, vol. 21, no. 1, pp. 19–23, 2011.
[3] C.-Y. Fan, C.-S. Lin, H.-L. Chao et al., "Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: a population-based cohort study," Radiotherapy and Oncology, vol. 123, no. 3, pp. 394–400, 2017.
[4] M. J. Boomsma, H. P. Bijl, and J. A. Langendijk, "Radiation-induced hypothyroidism in head and neck cancer patients: a systematic review," Radiotherapy and Oncology, vol. 99, no. 1, pp. 1–5, 2011.
[5] L. Chaker, A. C. Bianco, J. Jonklaas, and R. P. Peeters, "Hypothyroidism," The Lancet, vol. 390, no. 10101, pp. 1550–1562, 2017.
[6] J. Lang, C. Hu, T. Lu, J. Pan, and T. Lin, "Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives," Cancer Management and Research, vol. 11, pp. 6365–6376, 2019.
[7] L. Zhou, J. Chen, W. Shen et al., "Thyroid V50 is a risk factor for hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: a retrospective study," Radiation Oncology, vol. 15, no. 1, p. 68, 2020.
[8] V. Murthy, K. Narang, S. Ghosh-Laskar, T. Gupta, A. Budrukkar, and J. P. Agrawal, "Hypothyroidism after 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for head and neck cancers: prospective data from 2 randomized controlled trials," Head & Neck, vol. 36, no. 11, pp. 1573–1580, 2014.
[9] M. Fujiwara, N. Kamikonya, S. Odawara et al., "The threshold of hypothyroidism after radiation therapy for head and neck
cancer: a retrospective analysis of 116 cases,” Journal of Radiation Research, vol. 56, no. 3, pp. 577–582, 2015.

[10] M. W. van den Brekel, H. V. Stel, J. A. Casteljns et al., “Cervical lymph node metastasis: assessment of radiologic criteria,” Radiology, vol. 177, no. 2, pp. 379–384, 1990.

[11] V. Grégoire, K. Ang, W. Budach et al., “Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines,” Radiotherapy and Oncology, vol. 110, no. 1, pp. 172–181, 2014.

[12] V. Lee, S.-Y. Chan, C.-W. Choi et al., “Dosimetric predictors of hypothyroidism after radical intensity-modulated radiation therapy for non-metastatic nasopharyngeal carcinoma,” Clinical Oncology, vol. 28, no. 8, pp. e52–e60, 2016.

[13] C. Lertbutsayanukul, S. Kitpanit, A. Prayongrat, D. Kannarunimit, B. Netsawang, and C. Chakkabat, “Validation of previously reported predictors for radiation-induced hypothyroidism in nasopharyngeal cancer patients treated with intensity-modulated radiation therapy, a post hoc analysis from a Phase III randomized trial,” Journal of Radiation Research, vol. 59, no. 4, pp. 446–455, 2018.

[14] S. Ling, A. D. Bhatt, N. V. Brown et al., “Correlative study of dose to thyroid and incidence of subsequent dysfunction after head and neck radiation,” Head & Neck, vol. 39, no. 3, pp. 548–554, 2017.

[15] C. L. Huang, H. W. Tan, R. Guo et al., “Thyroid dose-volume thresholds for the risk of radiation-related hypothyroidism in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy-a single-institution study,” Cancer Medicine, vol. 8, no. 16, pp. 6887–6893, 2019.

[16] M. Koc and I1 Capoglu, “Thyroid dysfunction in patients treated with radiotherapy for neck,” American Journal of Clinical Oncology, vol. 32, no. 2, pp. 150–153, 2009.

[17] M. F. Ronjom, C. Brink, S. M. Bentzen, L. Hegedüs, J. Overgaard, and J. Johansen, “Hypothyroidism after primary radiotherapy for head and neck squamous cell carcinoma: normal tissue complication probability modeling with latent time correction,” Radiotherapy & Oncology, vol. 109, no. 2, pp. 317–322, 2013.